BURBANK, CA, Mar 08, 2010– Imaging3(TM), Inc., developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Wednesday, March 10, 2010 at 1:00pm PST, (4:00pm EST) the company’s CEO, Mr. Dean Janes, will be hosting a conference call. To join the conference call, please call 1-888-732-6202 and enter passcode 745546 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation.
The purpose of the call is to update Shareholders and other interested parties of the current developments with the company’s 510k FDA submission.
A limited number of lines will be available for this conference call. The lines will open up 5 minutes prior to the start of the call.
A recording of the conference call will be made available on the company’s website as soon as it is available. Imaging3 will notify shareholders and others who are on the company’s e-mail opt-in list. Anyone who would like to be added to this list is encouraged to sign-up for the e-mail based newsletter on the company’s website using the following link — http://www.imaging3.com/newsletters_signup.html.
About Imaging3 Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information
Safe Harbor Statement Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.